20/20 Biolabs reports Q2 GAAP EPS of -$0.26, revenue of $0.73M

Earnings
โดย Seeking Alpha·Read original
Summary · why it matters

20/20 Biolabs reported second quarter 2026 financial results with a GAAP EPS of negative $0.26 and revenue of $0.73 million, up 35.2% year over year. Gross profit increased 86.6% to $0.30 million, with gross margin expanding to 41.7%. Net loss was $1.51 million, compared to $0.84 million in the prior-year period. Cash and cash equivalents totaled $4.55 million as of June 30, 2026, up from $1.03 million at year-end 2025.

Impact on stocks 1

Biotech & Genomic Medicine▼ · 1 stocks
© 2026 MarketDXNews